Japan’s FY2025 Off-Cycle Drug Price Revision: Striking a Balance Between Cost Containment and Innovation
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
$2995
With off-cycle drug price revisions having been established since 2019, to operate in tandem with the traditional system of biennial revisions, GlobalData explores the impact of the fiscal year (FY) 2025 off-cycle price revision, in the context of ongoing pressures to save costs while at the same time combating drug lag and encouraging innovation.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
See what our customers are saying
Related reports
View more Product Type reports
New
New
New